BHST (BioHarvest Sciences) ROCE %: -18.11% (As of Mar. 2026)

What is BioHarvest Sciences ROCE %?

BioHarvest Sciences BHST -1.42% 64 ROCE % is -18.11% as of Mar. 2026. GuruFocus rates BHST with a GF Score™ of 64/100 and a GF Value™ of $8.57 (Possible Value Trap). The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. BioHarvest Sciences's annualized ROCE % for the quarter that ended in Mar. 2026 was -18.11%.

BioHarvest Sciences (NAS:BHST) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

BioHarvest Sciences ROCE % Related Terms

BioHarvest Sciences ROCE % Historical Data

* Premium members only.

The historical data trend for BioHarvest Sciences's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioHarvest Sciences ROCE % Chart

BioHarvest Sciences Annual Data

Trend

Apr16

Apr17

Apr18

Apr19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

-168.71

-381.35

0.00

-32.87

BioHarvest Sciences Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial															-74.74	-79.12	-22.51	-50.11	-18.11

64GF Score

BioHarvest Sciences Inc BHST

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

BioHarvest Sciences ROCE % Calculation

BioHarvest Sciences's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	-8.336	/	( ( (25.001 - 14.258)	+	(47.665 - 7.684) )	/ 2 )
	=	-8.336	/	( (10.743	+	39.981)	/ 2 )
	=	-8.336	/	25.362
	=	-32.87 %

BioHarvest Sciences's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	-6.88	/	( ( (47.665 - 7.684)	+	(45.558 - 9.578) )	/ 2 )
	=	-6.88	/	( ( 39.981	+	35.98 )	/ 2 )
	=	-6.88	/	37.9805
	=	-18.11 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of -18.11% mean?

BioHarvest Sciences (BHST) has a ROCE % of -18.11% as of Mar. 2026.

Is BioHarvest Sciences' ROCE % too high?

BioHarvest Sciences' current ROCE % is -18.11%. Overall, BioHarvest Sciences has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does BioHarvest Sciences' ROCE % compare to GWLL and CLNN?

BioHarvest Sciences' ROCE % of -18.11% can be compared against companies in the Consumer Packaged Goods industry. The industry median ROCE % is 8.78. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Consumer Packaged Goods company?

The median ROCE % among Consumer Packaged Goods companies is 8.78, based on 1,938 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Consumer Packaged Goods industry, the median ROCE % is 8.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioHarvest Sciences's current ROCE % is -18.11%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is BioHarvest Sciences stock overvalued right now?

Based on GuruFocus' analysis, BioHarvest Sciences (BHST) is currently considered Possible Value Trap. The stock's GF Value™ is $8.57, compared to a current price of $2.77 — trading 67.7% below its estimated fair value. The current ROCE % is -18.11%. BioHarvest Sciences' overall GF Score™ is 64/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For BioHarvest Sciences (BHST), the current ROCE % is -18.11% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioHarvest Sciences (BHST) Overvalued in 2026?

Based on GuruFocus' analysis, BioHarvest Sciences stock appears to be undervalued. The current stock price of $2.77 is trading 67.7% below its estimated GF Value™ of $8.57. GuruFocus considers BioHarvest Sciences to be Possible Value Trap.

Key valuation signals for BHST:

ROCE %: -18.11%
GF Value™: $8.57 vs. price of $2.77 (67.7% below fair value)
GF Score™: 64/100 with 4 warning signs

No single metric tells the full story. See the BHST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioHarvest Sciences Business Description

Industry Consumer Defensive Consumer Packaged Goods

Comparable Companies GWLL CLNN FTLF LFVN BRID HAIN SRXH DDC UMEW BOF XSWX:NESN XPAR:BN BOG:NUTRESA TSE:2802 SHSE:603288 NSE:NESTLEIND KHC SHSE:600887 SZSE:300999 GIS

Other Exchanges 8MV0:Germany

Address 1140-625 Howe Street, Vancouver, BC, CAN, V6C 2T6

Website https://www.bioharvest.com

BioHarvest Sciences Inc is the developer and owner of the patented bio-cell growth platform farming technology. The Company has two operating segments or business units: the Products business unit and the CDMO Services business unit. In identifying these operating segments, management generally follows the Company's service lines representing its main products and services. The Products Business Unit - Nutraceuticals: Research, development, manufacturing, marketing and sales of science-based health and wellness nutraceutical solutions which are manufactured and sold as dietary supplements, functional food and beverages. The CDMO Services Business Unit - comprising a Contract Development and Manufacturing Operation that offers pharmaceuticals, cosmeceuticals, nutraceuticals, and nutritions.

64GF Score

Get the complete analysis for BHST

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.77

Price

$8.57

GF Value

View BHST Analysis

See ROCE % data for all stocks →